David A. Sandham - Concepedia

Author

David A. Sandham

Novartis (Switzerland)ORCID

Also Known As

D. A. SANDHAM, D. Sandham, D.A. Sandham, David A Sandham, David A. Sandham, David Sandham, Sandham, David A.

Publications

829

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research Novartis (United Kingdom)Novartis (United States)University of Sussex

About

David A. Sandham is an author at Novartis (Switzerland) specializing in pharmacology, chemistry, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	225
2	Engineering	6	6	157
3	Biochemistry	4	4	89
4	Natural Sciences	3	3	81
5	Allergy	2	2	46

David A. Sandham

Publications

666

Citations

H-Index

Page 1

	Year	Citations
Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy David A. Sykes, Michelle Bradley, Darren Riddy, Molecular Pharmacology	2016	67
A convergent synthesis of the renin inhibitor CGP60536B David A. Sandham, Roger Taylor, John Carey, Tetrahedron Letters Combinatorial ChemistryMedicineRenin Inhibitor Cgp60536bPharmacologyDrug Discovery	2000	51
7-Azaindole-3-acetic acid derivatives: Potent and selective CRTh2 receptor antagonists David A. Sandham, Claire Adcock, Kamlesh Bala, Bioorganic & Medicinal Chemistry Letters MedicineMechanism Of ActionPharmacological Agent7-Azaindole-3-acetic Acid DerivativesPharmacotherapy	2009	43
Rhodium promoted isomerisation of allylic alkoxides: a new method for enolate anion formation Lewis Gazzard, William B. Motherwell, David A. Sandham Journal of the Chemical Society Perkin Transactions 1 Chemical EngineeringEnolate FormationEngineeringEnantioselective SynthesisNatural Sciences	1999	42
Uncoupling the Structure–Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding Callum J. Dickson, Viktor Horn̆ák, Camilo Velez‐Vega, Journal of Medicinal Chemistry	2016	36
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease Darren Le Grand, Martin Gosling, Urs Baettig, Journal of Medicinal Chemistry	2021	35
An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol David T. Beattie, David Beer, Michelle Bradley, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryβ2-Adrenoceptor Agonist IndacaterolMedicineMechanism Of Action	2012	32
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma David A. Sandham, Lucy Barker, Lyndon Brown, ACS Medicinal Chemistry Letters	2017	31
A one-step synthesis of tetrahydropyranopyranones from carbonyl compounds Alan Armstrong, Fred W. Goldberg, David A. Sandham Tetrahedron Letters Carbonyl CompoundsOrganic ChemistryChemistrySynthetic ChemistryEnantioselective Synthesis	2001	31
Chiral bicyclic lactams–an asymmetric synthesis of the framework of the Lycopodium alkaloid magellanine containing all six adjacent stereogenic centres David A. Sandham, A. I. MEYERS Journal of the Chemical Society Chemical Communications Chemical EngineeringEngineeringPhysicochemical AnalysisJ. ChemAdjacent Stereogenic Centres	1995	26

Page 1